Microbix and Aurevia Revolutionize Diagnostics with EQA Scheme
Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF) has partnered with Aurevia Oy to roll out an innovative external quality assessment (EQA) program aimed at supporting clinical laboratories in utilizing molecular diagnostic methods for diagnosing bacterial vaginosis (BV). This collaborative effort not only enhances the accuracy of testing but also significantly contributes to women's health.
Understanding Bacterial Vaginosis
Bacterial vaginosis is a prevalent condition impacting a significant number of women worldwide. It results from an imbalance in the vaginal bacterial flora, leading to the dominance of harmful species. Traditionally, BV was diagnosed based on physical symptoms such as changes in vaginal acidity and odor, as well as microbiological tests. However, these methods often lack the precision needed for definitive diagnoses.
Molecular Diagnostic Testing Comes to the Fore
Unlike previous diagnostic methods, molecular diagnostic (MDx) tests have revolutionized the identification of microbial imbalances. They enable the detection of specific organisms present in the vaginal flora, confirming whether their proportions are adequate. Hence, these tests not only offer definitive diagnoses but also aid in formulating effective treatment plans.
A Deep Dive into the EQA Program
The newly introduced EQA program, designated as number 5305, is designed to assist clinical laboratories in diagnosing BV as well as other vaginal infections like vulvovaginal candidiasis and trichomoniasis. This pilot study, facilitated through simulated samples created by Microbix (QAPs™), will validate the efficacy of MDx tests for BV and improve laboratory diagnostics.
The Role of Simulated Samples
Microbix has crafted three QAP samples, expertly formatted onto Copan® FLOQSwabs®, to mirror real clinical specimens safely and effectively. These samples streamline the workflow of MDx tests from specimen collection to results reporting, providing a realistic testing environment. Each QAP is designed to be non-infectious and stable at room temperature, ensuring a reliable diagnosis over an extended period.
Expert Insights on the EQA Program
Heidi Berghäll, EQA Solutions Manager at Aurevia, expressed the importance of validating emerging MDx tests for BV. She highlighted that an established EQA scheme can enhance laboratory performance, thereby facilitating improved access to timely clinical care and effective treatment options.
A Commitment to Quality and Accuracy
Cameron Groome, CEO & President of Microbix, remarked on the collaborative venture with Aurevia as a significant stride towards validating advanced diagnostic tests. Their collective goal is to be the leading partner for proficiency testing and quality assurance in the industry.
About Microbix Biosystems Inc.
Microbix is dedicated to creating proprietary biological products that enhance global health. With a skilled workforce of over 120 employees, they have established a monthly sales target of C$ 2.0 million. The company specializes in producing critical raw materials for the diagnostics industry, including antigens and QAPs™ that facilitate proficiency testing in clinical laboratories.
A Global Reach
Microbix's QAPs are now distributed across more than 30 nations, with a robust international distributor network supporting their global presence. The firm is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, and compliant with Health Canada regulations among other certifications.
About Aurevia OY
Aurevia operates as a full-service provider of External Quality Assessment Services (EQAS) and Contract Research Organization (CRO) solutions. Their focus is on advancing healthcare through stringent quality management and offering services that include quality assurance, clinical trials, and regulatory support.
Aurevia's Commitment to Excellence
Currently, Aurevia serves over 8,000 clients globally, showcasing their dedication to providing top-tier solutions in the healthcare sector. With a team of nearly 200 professionals across Europe, they strive for excellence in healthcare quality and patient safety.
Frequently Asked Questions
What is the purpose of the EQA program launched by Microbix and Aurevia?
The EQA program aims to assist clinical laboratories in accurately diagnosing bacterial vaginosis and other vaginal infections through enhanced quality assessment and validation of molecular diagnostic tests.
Why is bacterial vaginosis difficult to diagnose traditionally?
Traditional methods for diagnosing BV often lack precision, as they rely on subjective symptoms and microbiological assessments that may not be definitive.
How do QAPs enhance diagnostic testing?
QAPs simulate clinical specimens allowing for realistic testing scenarios, ensuring labs can assess their diagnostic capabilities accurately, leading to reliable patient outcomes.
What are the advantages of molecular diagnostic tests?
Molecular diagnostic tests provide specific organism detection and a clearer understanding of the vaginitis condition, enabling tailored treatment plans for patients.
How can interested parties inquire further about Microbix products?
Inquiries regarding Microbix QAPs can be directed to customer.service@microbix.com for thorough assistance.
